Wednesday, July 23, 2014 Last update: 12:33 PM - All Company Technology News Since 1996

Harvard Apparatus Regenerative Technology Schedules Release of Fourth Quarter and Year-End 2013 Financial Results and Investor Teleconference for March 7th

Companies mentioned in this article: Harvard Apparatus Regenerative Technology

HOLLISTON, Mass. -- (BUSINESS WIRE) -- Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its fourth quarter and year ended December 31, 2013 before market trading hours on Friday, March 7, 2014. A conference call to discuss the company’s fourth quarter and year-end results is scheduled for that same day at 11:00 AM (Eastern Time).

Participating in the call will be David Green, President and Chief Executive Officer, and Tom McNaughton, Chief Financial Officer, of HART.

Investors can access the live conference call by dialing the following phone numbers: toll-free 888-417-8533, or international: 719-325-2469, and referencing the pass code “1690076”.

If you are unable to listen to the live conference call, a replay will be available from approximately 2:00 PM (Eastern Time) on March 7, 2014 through March 14, 2014 and will be accessible by dialing toll free 888-203-1112, or toll and international 719-457-0820, and referencing the pass code “1690076”.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreathTM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Copyright © Business Wire 2014

Harvard Apparatus Regenerative Technology, Inc.:
David Green
President and CEO
Tom McNaughton
Investor Relations:
Dian Griesel Int’l.
Cheryl Schneider, 212-825-3210
Public Relations:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj, 212-825-3210